Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Subcutaneous 24-hour infusion of foslevodopa/foscarbidopa improves motor symptoms in PD patients

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, discusses the latest advancements in the delivery of levodopa for Parkinson’s disease. Traditionally, levodopa has been administered orally or through a percutaneous endoscopic gastrostomy. However, a new formulation allows for subcutaneous (SC) delivery of levodopa over 24 hours. This approach uses prodrugs that quickly phosphorylate once injected subcutaneously, offering several advantages. Firstly, the formulation allows for a higher dose of levodopa, covering the entire spectrum of possible doses for Parkinson’s disease patients. Additionally, it provides continuous delivery for 24 hours with customizable infusion rates. Importantly, the use of foslevodopa and foscarbidopa minimizes the risk of injection-site reactions, allowing for a needle to be left in the same spot for up to three days. This minimally invasive method significantly improves mobility and reduces dyskinesias, especially during early morning and nighttime periods. This strategy offers hope for Parkinson’s disease patients with motor fluctuations, providing sustained levodopa delivery. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.